Agomab Therapeutics has extended its cash runway into the first half of 2029 after raising $208 million in gross proceeds from a February IPO, alongside reporting year-end 2025 cash and equivalents of €116.5 million. With financing secured, the company is advancing two organ-restricted ALK5 (TGF-β receptor 1) inhibitors: a gut-restricted small molecule, ontunisertib, set to enter a Phase 2b study in fibrostenosing Crohn’s disease in the second half of 2026, and an inhaled candidate, AGMB-447, slated for a Phase 2 proof-of-concept trial in idiopathic pulmonary fibrosis on a similar timeline. Topline data from the STENOVA open-label extension in Crohn’s and a Phase 1b IPF cohort are expected in the second half of 2026.
The strategic signal is clear: Agomab is doubling down on local delivery of potent anti-fibrotic mechanisms to widen the therapeutic window where systemic TGF-β inhibition has historically stumbled on safety. If the company can translate early signals into durable disease modification in stricturing Crohn’s and lung fibrosis while maintaining tolerability, it could redefine how fibrosis is treated across organs. The bigger question for industry observers is whether organ-restricted TGF-β modulation can finally crack fibrosis biology at clinically meaningful, payer-relevant endpoints without triggering the adverse effects that derailed prior systemic approaches.
This matters now because both indications sit at the intersection of unmet need and payer scrutiny. In fibrostenosing Crohn’s, current anti-inflammatory biologics have limited impact on established strictures, leaving surgery as the default for many patients. Positive FDA interactions on the Phase 2b design suggest alignment on endpoints that can credibly capture structural change, an area historically challenged by variability in imaging and symptom correlations. The upcoming 48-week open-label extension readout, with ongoing 200 mg twice-daily dosing and no safety flags to date from the monitoring board, could offer a first look at whether prolonged exposure impacts stricture progression and surgery avoidance. For Medical Affairs, the burden will be to standardize imaging-based assessments, validate biomarkers, and frame patient-reported outcomes that translate to real-world reductions in procedures and hospitalizations.
In IPF, AGMB-447 enters a crowded but innovation-hungry field dominated by nintedanib and pirfenidone, where tolerability and slowing lung function decline remain the bar. Inhaled delivery of an ALK5 inhibitor, supported by UK regulator advice and now backed by US composition-of-matter protection, positions Agomab to test whether high local lung exposure can deliver efficacy without systemic liabilities. The short Phase 1b multiple-dose cohort this year will likely be scrutinized for safety, pharmacokinetics, and early pharmacodynamic signals that could de-risk Phase 2 design. Success would align with a broader industry pivot toward organ-targeted anti-fibrotics, seen in integrin and autotaxin programs attempting to localize activity and minimize off-target effects.
Financially, Agomab increased R&D spend to €48.9 million in 2025 and posted a €62.5 million net loss, but the post-IPO balance sheet reduces near-term financing risk and gives the company room to run both mid-stage trials without forced partnering. That optionality is strategically valuable in a market where large pharma is selectively re-entering IBD and respiratory fibrosis via partnerships and bolt-on acquisitions, rewarding assets with clean mid-stage data and clear regulatory pathways.
The next 12 months compress critical catalysts—Phase 1b and open-label extension readouts, Phase 2 initiations, and deeper regulatory engagement—into a window that can validate both the organ-restricted thesis and Agomab’s standalone trajectory. If the data cooperate, the question shifts from scientific plausibility to competitive positioning: can localized ALK5 inhibition secure a differentiated label and value narrative strong enough to challenge entrenched standards and attract the kind of BD interest that reshapes the fibrosis landscape?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
